Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1CD20-positive Hematological Malignancies 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Bevacizumab 37Oxaliplatin 17Capecitabine 17Irinotecan 15Leucovorin 13HMPL-013 12Fluorouracil 12Cetuximab 11trifluridine tipiracil drug combination 7irinotecan sucrosofate 6tipiracil 5Trifluridine 5Specimen Handling 5Drug Therapy 5tislelizumab 4Standard of Care 4Mitomycin 4Magnetic Resonance Spectroscopy 4Injections 4Folfox protocol 4trametinib 3toripalimab 3pembrolizumab 3Nivolumab 3IFL protocol 3Colonoscopy 3Blood Specimen Collection 3Biopsy 3sotorasib 2sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Colorectal Neoplasms × Injections, Subcutaneous × Clear all
NCT07036185 2025-06-25

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Shanghai Bao Pharmaceuticals Co., Ltd.

Phase 1 Not yet recruiting
66 enrolled
BreastGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡